{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T05:59:55Z","timestamp":1784354395018,"version":"3.55.0"},"reference-count":185,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.jaad.2010.06.017","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T06:58:16Z","timestamp":1283237896000},"page":"e195-e213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Cutaneous lupus erythematosus: Update of therapeutic options"],"prefix":"10.1016","volume":"65","author":[{"given":"Annegret","family":"Kuhn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Ruland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Bonsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2010.06.017_bib1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1529-8019.2007.00135.x","article-title":"Methotrexate in dermatology","volume":"20","author":"Bangert","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2010.06.017_bib2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1067\/mjd.2002.114608","article-title":"Methotrexate treatment for refractory subacute cutaneous lupus erythematosus","volume":"46","author":"Kuhn","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000246141","article-title":"Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate","volume":"194","author":"Bohm","year":"1997","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2010.06.017_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2133.2005.06552.x","article-title":"Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients","volume":"153","author":"Wenzel","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s002960050058","article-title":"Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms","volume":"18","author":"Boehm","year":"1998","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jaad.2010.06.017_bib6","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2133.1995.tb02726.x","article-title":"Methotrexate for the treatment of discoid lupus erythematosus","volume":"133","author":"Bottomley","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib7","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archderm.1994.01690070134027","article-title":"Discoid lupus erythematosus: successful treatment with oral methotrexate","volume":"130","author":"Goldstein","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib8","first-page":"620","article-title":"A case of pediatric discoid lupus erythematosus evolving into SLE","volume":"16","author":"Picco","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2006.07431.x","article-title":"Methotrexate treatment in cutaneous lupus erythematosus: subcutaneous application is as effective as intravenous administration","volume":"155","author":"Huber","year":"2006","journal-title":"Br J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib10","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0190-9622(93)70069-6","article-title":"Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis","volume":"28","author":"Duhra","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib11","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1046\/j.1365-2133.2001.03959.x","article-title":"The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up","volume":"144","author":"Zachariae","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib12","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1468-3083.2001.t01-1-00223.x","article-title":"Pneumonitis complicating methotrexate therapy for pustular psoriasis","volume":"15","author":"Ameen","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib13","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0190-9622(96)90039-0","article-title":"Guidelines of care for cutaneous lupus erythematosus: American Academy of Dermatology","volume":"34","author":"Drake","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2340\/0001555565324329","article-title":"Treatment of cutaneous lupus erythematosus with etretinate","volume":"65","author":"Ruzicka","year":"1985","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/archderm.1988.01670060043013","article-title":"Efficiency of acitretin in the treatment of cutaneous lupus erythematosus","volume":"124","author":"Ruzicka","year":"1988","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2133.1992.tb14851.x","article-title":"Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine","volume":"127","author":"Ruzicka","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/archderm.1986.01660140060018","article-title":"Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus","volume":"122","author":"Newton","year":"1986","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib18","first-page":"311","article-title":"Use of oral isotretinoin in the treatment of cutaneous lupus erythematosus","volume":"124","author":"Vena","year":"1989","journal-title":"G\u00a0Ital Dermatol Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-4362.1990.tb03476.x","article-title":"Subacute cutaneous lupus erythematosus response to isotretinoin","volume":"29","author":"Furner","year":"1990","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0190-9622(91)70008-P","article-title":"Isotretinoin for refractory lupus erythematosus","volume":"24","author":"Shornick","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib21","first-page":"183","article-title":"Subacute cutaneous lupus erythematosus: report of a patient who subsequently developed a meningioma and whose skin lesions were treated with isotretinoin","volume":"66","author":"Richardson","year":"2000","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2010.06.017_bib22","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1346-8138.2005.tb00785.x","article-title":"Hypertrophic lupus erythematosus treated successfully with acitretin as monotherapy","volume":"32","author":"Al-Mutairi","year":"2005","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib23","series-title":"Cutaneous lupus erythematosus","first-page":"373","article-title":"Dapsone and retinoids","author":"Bacman","year":"2004"},{"key":"10.1016\/j.jaad.2010.06.017_bib24","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1067\/mjd.2001.114733","article-title":"Dapsone and sulfones in dermatology: overview and update","volume":"45","author":"Zhu","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1440-0960.2008.00437.x","article-title":"Bullous systemic lupus erythematosus responding to dapsone","volume":"49","author":"Ludgate","year":"2008","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1365-2133.1981.tb01711.x","article-title":"Dapsone in the treatment of lupus erythematosus","volume":"104","author":"Ruzicka","year":"1981","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1365-2133.1982.tb00910.x","article-title":"Dapsone and discoid lupus erythematosus","volume":"106","author":"Coburn","year":"1982","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000249338","article-title":"Dapsone in the treatment of cutaneous lupus erythematosus","volume":"172","author":"Lindskov","year":"1986","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2010.06.017_bib29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s001050050763","article-title":"ANCA-positive lupus erythematodes profundus: successful therapy with low dosage dapsone","volume":"49","author":"Bohm","year":"1998","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaad.2010.06.017_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0190-9622(84)70180-0","article-title":"Annular subacute cutaneous lupus erythematosus responsive to dapsone","volume":"11","author":"McCormack","year":"1984","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib31","first-page":"1222","article-title":"Dapsone is an effective therapy for the skin lesions of subacute cutaneous lupus erythematosus and urticarial vasculitis in a patient with C2 deficiency","volume":"17","author":"Holtman","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2230.1986.tb00433.x","article-title":"Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus","volume":"11","author":"Fenton","year":"1986","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1346-8138.1989.tb01284.x","article-title":"Lupus erythematosus profundus\u2013report of a case treated with dapsone","volume":"16","author":"Yamada","year":"1989","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib34","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archderm.142.3.399","article-title":"Lupus erythematosus profundus successfully treated with dapsone: review of the literature","volume":"142","author":"Ujiie","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0889-857X(21)00373-2","article-title":"Treatment of refractory cutaneous lupus erythematosus","volume":"21","author":"Duna","year":"1995","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2010.06.017_bib36","first-page":"1","article-title":"Dapson\u2013Pharmakologie, Wirkungsmechanismus und klinischer Einsatz in der Dermatologie","volume":"179","author":"Wozel","year":"1993","journal-title":"Dermatol Monatsschr"},{"key":"10.1016\/j.jaad.2010.06.017_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0300-483X(01)00360-2","article-title":"Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention","volume":"162","author":"Coleman","year":"2001","journal-title":"Toxicology"},{"key":"10.1016\/j.jaad.2010.06.017_bib38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1529-8019.2007.00136.x","article-title":"Mycophenolate mofetil","volume":"20","author":"Zwerner","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2010.06.017_bib39","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib40","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1001\/archderm.142.11.1447","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus","volume":"142","author":"Beissert","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib41","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2215\/CJN.01200307","article-title":"Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis","volume":"2","author":"Walsh","year":"2007","journal-title":"Clin J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jaad.2010.06.017_bib42","first-page":"132","article-title":"An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases","volume":"5","author":"Appel","year":"2009","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.jaad.2010.06.017_bib43","first-page":"235","article-title":"Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil","volume":"137","author":"Boehm","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1067\/mjd.2001.114297","article-title":"Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil","volume":"45","author":"Goyal","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2133.2002.04875.x","article-title":"Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil","volume":"147","author":"Schanz","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-4632.2004.02472.x","article-title":"Coexisting subacute and systemic lupus erythematosus after terbinafine administration: successful treatment with mycophenolate mofetil","volume":"45","author":"Cetkovska","year":"2006","journal-title":"Int J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib47","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1001\/archderm.138.12.1616","article-title":"Mycophenolate mofetil for the treatment of cutaneous lupus erythematosus with smoldering systemic involvement","volume":"138","author":"Hanjani","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib48","first-page":"393","article-title":"Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil","volume":"23","author":"Pisoni","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib49","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/rheumatology\/41.8.876","article-title":"Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents","volume":"41","author":"Karim","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl","key":"10.1016\/j.jaad.2010.06.017_bib50","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1191\/0961203305LU2111OA","article-title":"Mycophenolate mofetil and systemic lupus erythematosus: an overview","volume":"14","author":"Pisoni","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2010.06.017_bib51","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/j.1365-2133.2007.07826.x","article-title":"Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy","volume":"156","author":"Kreuter","year":"2007","journal-title":"Br J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib52","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2133.2004.06117.x","article-title":"Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus: discordant effects on minimal erythema dose and sunburn cell formation","volume":"151","author":"Cummins","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib53","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1600-0781.2003.00055.x","article-title":"Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways","volume":"19","author":"Lu","year":"2003","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2010.06.017_bib54","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: dermatological indications, mechanisms of action and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib55","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","article-title":"Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses","volume":"35","author":"Tseng","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib56","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2133.1983.tb04600.x","article-title":"Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus","volume":"108","author":"Knop","year":"1983","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib57","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s001050170091","article-title":"Wiederentdeckung von Thalidomid","volume":"52","author":"Kuhn","year":"2001","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaad.2010.06.017_bib58","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.amjmed.2004.04.030","article-title":"Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens","volume":"118","author":"Cuadrado","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.jaad.2010.06.017_bib59","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1212\/01.WNL.0000130499.91775.2C","article-title":"Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus","volume":"62","author":"Briani","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2010.06.017_bib60","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0149-2918(00)88289-2","article-title":"S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide","volume":"21","author":"Zeldis","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2010.06.017_bib61","first-page":"63","article-title":"Transient secondary amenorrhea in women treated by thalidomide","volume":"12","author":"Frances","year":"2002","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib62","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1191\/0961203305lu2124oa","article-title":"Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients","volume":"14","author":"Coelho","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2010.06.017_bib63","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.2000.00953.x","article-title":"Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus","volume":"39","author":"Kyriakis","year":"2000","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib64","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/leu.2008.123","article-title":"Treatment of plasma cell dyscrasias with lenalidomide","volume":"22","author":"Dimopoulos","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2010.06.017_bib65","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/archdermatol.2009.30","article-title":"Lenalidomide for the treatment of resistant discoid lupus erythematosus","volume":"145","author":"Shah","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib66","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1212\/WNL.0b013e3181b6bb22","article-title":"Myeloma-associated polyneuropathy responding to lenalidomide","volume":"73","author":"Layzer","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2010.06.017_bib67","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1529-8019.2007.00142.x","article-title":"The use of i.v. IG therapy in dermatology","volume":"20","author":"Fernandez","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2010.06.017_bib68","first-page":"304","article-title":"High-dose immuno-globulins in the treatment of refractory cutaneous lupus erythematosus: open trial in 5 cases","volume":"38","author":"Piette","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib69","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/archderm.135.9.1124","article-title":"High-dose intravenous immunoglobulin in cutaneous lupus erythematosus","volume":"135","author":"Genereau","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib70","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10067-006-0222-5","article-title":"Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative","volume":"26","author":"Lampropoulos","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/09546630310018789","article-title":"Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE)","volume":"15","author":"Goodfield","year":"2004","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2010.06.017_bib72","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/00015550510037071","article-title":"Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus","volume":"85","author":"Kreuter","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib73","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/096120339700600414","article-title":"Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus","volume":"6","author":"De Pita","year":"1997","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2010.06.017_bib74","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s12016-009-8162-x","article-title":"Intravenous immunoglobulin in lupus panniculitis","volume":"38","author":"Espirito Santo","year":"2010","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaad.2010.06.017_bib75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0190-9622(95)90134-5","article-title":"Clofazimine: a review of its medical uses and mechanisms of action","volume":"32","author":"Arbiser","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib76","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2133.1974.tb06723.x","article-title":"Clofazimine in the treatment of discoid lupus erythematosus","volume":"91","author":"Mackey","year":"1974","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib77","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archderm.1981.01650050003002","article-title":"Clofazimine in the treatment of annular lupus erythematosus","volume":"117","author":"Crovato","year":"1981","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib78","first-page":"423","article-title":"Lamprene (Clofazimine) treatment of chronic lupus erythematoides (author's transl)","volume":"105","author":"Dupre","year":"1978","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib79","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1440-0960.1976.tb00801.x","article-title":"Clofazimine (laprene) in the treatment of discoid lupus erythematosus","volume":"17","author":"Krivanek","year":"1976","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib80","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1440-0960.1980.tb00162.x","article-title":"Further study of the use of clofazimine in discoid lupus erythematosus","volume":"21","author":"Krivanek","year":"1980","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib81","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/art.21358","article-title":"Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus","volume":"52","author":"Bezerra","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib82","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","article-title":"Azathioprine in dermatology: the past, the present, and the future","volume":"55","author":"Patel","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib83","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/qjmed\/95.7.439","article-title":"Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK","volume":"95","author":"Holme","year":"2002","journal-title":"QJM"},{"key":"10.1016\/j.jaad.2010.06.017_bib84","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/archderm.1991.04510010083008","article-title":"Azathioprine: an effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis","volume":"127","author":"Callen","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib85","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0190-9622(88)70259-5","article-title":"Resistant discoid lupus erythematosus of palms and soles: successful treatment with azathioprine","volume":"19","author":"Ashinoff","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib86","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archderm.1985.01660100103026","article-title":"Successful treatment of generalized discoid skin lesions with azathioprine: its use in a patient with systemic lupus erythematosus","volume":"121","author":"Tsokos","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib87","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1001\/archderm.1986.01660160026007","article-title":"Successful treatment of generalized discoid skin lesions with azathioprine","volume":"122","author":"Shehade","year":"1986","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib88","first-page":"459","article-title":"Lupus erythematosus with an erythema multiforme-like eruption","volume":"10","author":"Roustan","year":"2000","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib89","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1529-8019.2007.00134.x","article-title":"Azathioprine: a guide for the management of dermatology patients","volume":"20","author":"Wise","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2010.06.017_bib90","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0889-857X(21)00234-9","article-title":"Immunosuppressive drug therapy of systemic lupus erythematosus","volume":"20","author":"Fox","year":"1994","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.jaad.2010.06.017_bib91","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S0733-8635(05)70194-7","article-title":"Pulse intravenous cyclophosphamide therapy for dermatologic disorders","volume":"18","author":"Fox","year":"2000","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2010.06.017_bib92","doi-asserted-by":"crossref","first-page":"79","DOI":"10.7326\/0003-4819-106-1-79","article-title":"NIH conference: lupus nephritis","volume":"106","author":"Balow","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2010.06.017_bib93","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/art.10752","article-title":"High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus","volume":"48","author":"Petri","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib94","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2133.1971.tb14112.x","article-title":"Treatment of discoid and subacute lupus erythematosus with cyclophosphamide","volume":"85","author":"Schulz","year":"1971","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib95","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.1780380815","article-title":"Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20-year followup study","volume":"38","author":"Radis","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib96","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1529-8019.2007.00137.x","article-title":"Systemic cyclosporine and tacrolimus in dermatology","volume":"20","author":"Madan","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2010.06.017_bib97","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s005990070017","article-title":"Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus","volume":"30","author":"Dammacco","year":"2000","journal-title":"Int J Clin Lab Res"},{"key":"10.1016\/j.jaad.2010.06.017_bib98","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/art.1780400106","article-title":"Long-term treatment of systemic lupus erythematosus with cyclosporin A","volume":"40","author":"Caccavo","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib99","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2230.1995.tb01315.x","article-title":"Coexisting lichen planus and subacute cutaneous lupus erythematosus","volume":"20","author":"Grabbe","year":"1995","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib100","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1191\/096120300678828406","article-title":"Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A","volume":"9","author":"Saeki","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2010.06.017_bib101","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/archderm.1986.01660210021007","article-title":"Cyclosporine in the treatment of lupus erythematosus","volume":"122","author":"Heule","year":"1986","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib102","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2133.1994.tb08471.x","article-title":"Cyclosporin and discoid lupus erythematosus","volume":"131","author":"Yell","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib103","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/00015550152573119","article-title":"Discoid lupus erythematosus in a patient receiving cyclosporine for liver transplantation","volume":"81","author":"Obermoser","year":"2001","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib104","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2340\/00015555768788","article-title":"Discoid lupus erythematosus during treatment with cyclosporine","volume":"76","author":"Di Lernia","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib105","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1172\/JCI992","article-title":"Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B","volume":"101","author":"Wahl","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2010.06.017_bib106","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-4362.1996.tb00657.x","article-title":"Efficacy of sulfasalazine in discoid lupus erythematosus","volume":"35","author":"Artuz","year":"1996","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib107","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2133.1991.tb14757.x","article-title":"Discoid lupus erythematosus responsive to sulphasalazine","volume":"125","author":"Carmichael","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib108","first-page":"151","article-title":"Treatment of discoid lupus erythematosus with sulfasalazine: 11 cases","volume":"124","author":"Delaporte","year":"1997","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib109","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1440-0960.2006.00217.x","article-title":"Cutaneous lupus erythematosus: a personal approach to management","volume":"47","author":"Callen","year":"2006","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib110","first-page":"2157","article-title":"Antihistone antibody profile in sulfasalazine induced lupus","volume":"21","author":"Bray","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib111","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000018345","article-title":"Long-term cefuroxime axetil in subacute cutaneous lupus erythematosus: a report of three cases","volume":"200","author":"Rudnicka","year":"2000","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2010.06.017_bib112","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000247940","article-title":"Danazol and discoid lupus erythematosus","volume":"181","author":"Torrelo","year":"1990","journal-title":"Dermatologica"},{"key":"10.1016\/j.jaad.2010.06.017_bib113","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2133.1988.tb03239.x","article-title":"Danazol and discoid lupus","volume":"119","author":"Englert","year":"1988","journal-title":"Br J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib114","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.1990.tb01853.x","article-title":"Discoid lupus erythematosus associated with hereditary angioneurotic edema","volume":"123","author":"Duhra","year":"1990","journal-title":"Br J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib115","first-page":"CD005114","article-title":"Dehydroepiandrosterone for systemic lupus erythematosus","volume":"4","author":"Crosbie","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2010.06.017_bib116","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/art.1780281108","article-title":"Hormonal modulation in systemic lupus erythematosus: preliminary clinical and hormonal results with cyproterone acetate","volume":"28","author":"Jungers","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib117","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jaad.2009.02.039","article-title":"Extracorporeal photopheresis: past, present, and future","volume":"61","author":"Knobler","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib118","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s001050050775","article-title":"Extracorporeal photopheresis in therapy-refractory disseminated discoid lupus erythematosus","volume":"49","author":"Richter","year":"1998","journal-title":"Hautarzt"},{"key":"10.1016\/j.jaad.2010.06.017_bib119","first-page":"1023","article-title":"Extracorporeal photochemotherapy in therapy-refractory subacute lupus","volume":"129","author":"Richard","year":"2002","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib120","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1468-3083.1999.tb00866.x","article-title":"Extracorporeal photochemotherapy in cutaneous lupus erythematosus","volume":"13","author":"Wollina","year":"1999","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib121","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1111\/j.1365-2230.2009.03239.x","article-title":"Extracorporeal photopheresis in recalcitrant lupus erythematosus","volume":"34","author":"Boeckler","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib122","first-page":"365","article-title":"Successful preventive treatment of congenital heart block during pregnancy in a\u00a0woman with systemic lupus erythematosus and anti-Sjogren's syndrome A\/Ro antibody","volume":"38","author":"Yang","year":"2005","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jaad.2010.06.017_bib123","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0190-9622(96)80119-8","article-title":"Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412","volume":"34","author":"Prinz","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib124","doi-asserted-by":"crossref","first-page":"142S","DOI":"10.1111\/1523-1747.ep12875049","article-title":"Response of discoid and subacute cutaneous lupus erythematosus to recombinant interferon alpha 2a","volume":"95","author":"Nicolas","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.1990.tb08290.x","article-title":"Recombinant interferon alpha 2a is effective in the treatment of discoid and subacute cutaneous lupus erythematosus","volume":"122","author":"Thivolet","year":"1990","journal-title":"Br J\u00a0Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib126","first-page":"253","article-title":"Therapy of cutaneous lupus erythematosus with recombinant interferon alpha-2a: a case report","volume":"2","author":"Tebbe","year":"1992","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib127","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2796.1990.tb00144.x","article-title":"Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumor","volume":"227","author":"Ronnblom","year":"1990","journal-title":"J Intern Med"},{"issue":"Suppl","key":"10.1016\/j.jaad.2010.06.017_bib128","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-0560.2007.00715.x","article-title":"Lupus-like reaction to interferon at the injection site: report of five cases","volume":"34","author":"Arrue","year":"2007","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2010.06.017_bib129","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/j.1346-8138.1993.tb01316.x","article-title":"Long-term results of intralesional interferon alpha-2B in discoid lupus erythematosus","volume":"20","author":"Martinez","year":"1993","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib130","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0190-9622(08)80583-X","article-title":"Low-dose intralesional interferon alfa for discoid lupus erythematosus","volume":"26","author":"Martinez","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib131","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1046\/j.1365-2230.2002.01150.x","article-title":"Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases","volume":"27","author":"Frieling","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib132","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1191\/0961203304lu1067sr","article-title":"Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus","volume":"13","author":"Tam","year":"2004","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2010.06.017_bib133","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1191\/096120301678416033","article-title":"Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study","volume":"10","author":"Remer","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2010.06.017_bib134","first-page":"189","article-title":"Subacute cutaneous lupus erythematosus associated with leflunomide","volume":"76","author":"Elias","year":"2005","journal-title":"Cutis"},{"key":"10.1016\/j.jaad.2010.06.017_bib135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2230.2004.01527.x","article-title":"Subacute cutaneous lupus erythematosus associated with leflunomide","volume":"29","author":"Kerr","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib136","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1365-2230.2005.01898.x","article-title":"Subacute cutaneous lupus erythematosus precipitated by leflunomide","volume":"30","author":"Chan","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib137","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/rheumatology\/keh586","article-title":"Leflunomide-induced subacute cutaneous lupus erythematosus","volume":"44","author":"Goeb","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2010.06.017_bib138","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0961203307087189","article-title":"Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions","volume":"17","author":"Marzano","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2010.06.017_bib139","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2003.019323","article-title":"Lupus erythematosus with leflunomide: induction or reactivation?","volume":"64","author":"Gensburger","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2010.06.017_bib140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-4632.2007.03333.x","article-title":"Leflunomide in subacute cutaneous lupus erythematosus\u2013two sides of a coin","volume":"47","author":"Suess","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib141","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrd1175","article-title":"Anti-TNF-alpha therapies: the next generation","volume":"2","author":"Palladino","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2010.06.017_bib142","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.06.017_bib143","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1529-8019.2007.00138.x","article-title":"TNF-alpha inhibitors","volume":"20","author":"Jackson","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2010.06.017_bib144","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2133.2009.09331.x","article-title":"Tuberculosis screening in patients with psoriasis before antitumor necrosis factor therapy: comparison of an interferon-gamma release assay vs tuberculin skin test","volume":"161","author":"Laffitte","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib145","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00393-009-0475-x","article-title":"Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases","volume":"68","author":"Diel","year":"2009","journal-title":"Z Rheumatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib146","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib147","first-page":"2557","article-title":"Induction of autoantibodies during prolonged therapy with infliximab","volume":"30","author":"Louis","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib148","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.semarthrit.2007.08.003","article-title":"Drug-induced lupus due to anti-tumor necrosis factor alpha agents","volume":"37","author":"Costa","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib149","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10067-002-0654-5","article-title":"Anti-TNF-alpha-induced systemic lupus syndrome","volume":"22","author":"Debandt","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib150","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0025-6196(11)60668-X","article-title":"Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic","volume":"84","author":"Wetter","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaad.2010.06.017_bib151","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jaad.2010.06.017_bib152","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib153","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/art.22327","article-title":"Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus","volume":"56","author":"Aringer","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib154","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1016\/S0190-9622(03)00869-7","article-title":"Cutaneous lupus erythematosus induced by infliximab","volume":"52","author":"High","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib155","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0151-9638(05)79281-4","article-title":"Worsening of subacute lupus erythematosus induced by infliximab","volume":"132","author":"Vabre-Latre","year":"2005","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2010.06.017_bib156","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2230.2004.01471.x","article-title":"Discoid lupus erythematosus-like eruption induced by infliximab","volume":"29","author":"Stratigos","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib157","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ejim.2006.02.010","article-title":"Infliximab-induced non-specific interstitial pneumonia and lupus-like eruption","volume":"17","author":"Pataka","year":"2006","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jaad.2010.06.017_bib158","first-page":"760","article-title":"Infliximab induced chilblain lupus in a patient with rheumatoid arthritis","volume":"32","author":"Richez","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib159","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/archderm.142.1.115","article-title":"Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis","volume":"142","author":"Schneider","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib160","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.10271","article-title":"Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent","volume":"46","author":"Fautrel","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.jaad.2010.06.017_bib161","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1016\/j.jaad.2005.11.1090","article-title":"Case reports of etanercept in inflammatory dermatoses","volume":"54","author":"Norman","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib162","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/40.11.1317","article-title":"Etanercept-induced subacute cutaneous lupus erythematosus","volume":"40","author":"Bleumink","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2010.06.017_bib163","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2230.2007.02503.x","article-title":"Adalimumab-induced cutaneous lupus","volume":"32","author":"Sheth","year":"2007","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2010.06.017_bib164","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.jaad.2007.01.040","article-title":"Drug-induced lupus erythematosus in a patient treated with adalimumab","volume":"56","author":"Spillane","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib165","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/0961203307088291","article-title":"Adalimumab-induced lupus erythematosus","volume":"17","author":"Martin","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2010.06.017_bib166","first-page":"796","article-title":"Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab","volume":"7","author":"Havel","year":"2008","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib167","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","article-title":"Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis","volume":"20","author":"Stokes","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl","key":"10.1016\/j.jaad.2010.06.017_bib168","doi-asserted-by":"crossref","first-page":"iv55","DOI":"10.1136\/ard.2005.042648","article-title":"Update on rituximab","volume":"64","author":"Eisenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2010.06.017_bib169","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2008.11.006","article-title":"Use of rituximab in patients with systemic lupus erythematosus: an update","volume":"8","author":"Garcia-Carrasco","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jaad.2010.06.017_bib170","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/kel162","article-title":"Therapy-resistant lupus skin disease successfully treated with rituximab","volume":"45","author":"Risselada","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2010.06.017_bib171","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000112938","article-title":"Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case","volume":"216","author":"Uthman","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2010.06.017_bib172","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1440-0960.2009.00539.x","article-title":"Refractory subacute cutaneous lupus erythematosus successfully treated with rituximab","volume":"50","author":"Kieu","year":"2009","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib173","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1529-8019.2007.00139.x","volume":"20","author":"Chacko","year":"2007","journal-title":"Efalizumab. Dermatol Ther"},{"key":"10.1016\/j.jaad.2010.06.017_bib174","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaad.2005.08.025","article-title":"Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab","volume":"54","author":"Clayton","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib175","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1001\/archderm.143.7.873","article-title":"Efalizumab in the treatment of discoid lupus erythematosus","volume":"143","author":"Usmani","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib176","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2230.2007.02648.x","article-title":"Successful treatment of recalcitrant malar rash in a patient with cutaneous lupus erythematosus with efalizumab","volume":"33","author":"Hamprecht","year":"2008","journal-title":"Clin Exp Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2010.06.017_bib177","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1016\/j.jaad.2005.10.037","article-title":"Efalizumab-induced subacute cutaneous lupus erythematosus","volume":"54","author":"Bentley","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib178","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1177\/0961203309106761","article-title":"Efalizumab for subacute cutaneous lupus: report of two different outcomes","volume":"18","author":"Sanchez-Cano","year":"2009","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2010.06.017_bib179","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jaad.2010.06.017_bib180","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/archderm.1995.01690170124029","article-title":"Phenytoin in the treatment of discoid lupus erythematosus","volume":"131","author":"Rodriguez-Castellanos","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib181","first-page":"6","article-title":"Phenytoin in cutaneous medicine: its uses, mechanisms and side effects","volume":"9","author":"Scheinfeld","year":"2003","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2010.06.017_bib182","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/art.1780251121","article-title":"Systemic lupus erythematous triggered by diphenylhydantoin","volume":"25","author":"Gleichman","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.06.017_bib183","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1046\/j.1365-2230.2002.01107.x","article-title":"Subacute cutaneous lupus erythematosus associated with phenytoin","volume":"27","author":"Ross","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib184","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2133.1986.tb05720.x","article-title":"Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin)","volume":"115","author":"Dalziel","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.06.017_bib185","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/09546639109089051","article-title":"Auranofin in the treatment of discoid lupus erythematosus","volume":"2","author":"Steinkjer","year":"1991","journal-title":"J Dermatolog Treat"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210006985?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210006985?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:22:15Z","timestamp":1759270935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962210006985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":185,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0190962210006985"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2010.06.017","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous lupus erythematosus: Update of therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2010.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}